Evoke Pharma (EVOK) Competitors $2.15 0.00 (0.00%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVOK vs. BCAB, MIRA, ME, NRSN, CLDI, SLGL, MEIP, COCP, SYBX, and IPAShould you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include BioAtla (BCAB), MIRA Pharmaceuticals (MIRA), 23andMe (ME), NeuroSense Therapeutics (NRSN), Calidi Biotherapeutics (CLDI), Sol-Gel Technologies (SLGL), MEI Pharma (MEIP), Cocrystal Pharma (COCP), Synlogic (SYBX), and ImmunoPrecise Antibodies (IPA). These companies are all part of the "pharmaceutical products" industry. Evoke Pharma vs. BioAtla MIRA Pharmaceuticals 23andMe NeuroSense Therapeutics Calidi Biotherapeutics Sol-Gel Technologies MEI Pharma Cocrystal Pharma Synlogic ImmunoPrecise Antibodies BioAtla (NASDAQ:BCAB) and Evoke Pharma (NASDAQ:EVOK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings, profitability and community ranking. Which has higher valuation and earnings, BCAB or EVOK? Evoke Pharma has lower revenue, but higher earnings than BioAtla. Evoke Pharma is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAtla$11M1.73-$123.46M-$1.44-0.23Evoke Pharma$10.25M0.29-$7.79M-$4.40-0.46 Is BCAB or EVOK more profitable? BioAtla has a net margin of 0.00% compared to Evoke Pharma's net margin of -71.32%. BioAtla's return on equity of -187.30% beat Evoke Pharma's return on equity.Company Net Margins Return on Equity Return on Assets BioAtlaN/A -187.30% -96.33% Evoke Pharma -71.32%-308.49%-53.66% Does the media favor BCAB or EVOK? In the previous week, Evoke Pharma had 2 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Evoke Pharma and 0 mentions for BioAtla. BioAtla's average media sentiment score of 1.87 beat Evoke Pharma's score of 0.30 indicating that BioAtla is being referred to more favorably in the media. Company Overall Sentiment BioAtla Very Positive Evoke Pharma Neutral Which has more risk and volatility, BCAB or EVOK? BioAtla has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Evoke Pharma has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Does the MarketBeat Community favor BCAB or EVOK? Evoke Pharma received 335 more outperform votes than BioAtla when rated by MarketBeat users. However, 65.79% of users gave BioAtla an outperform vote while only 58.16% of users gave Evoke Pharma an outperform vote. CompanyUnderperformOutperformBioAtlaOutperform Votes2565.79% Underperform Votes1334.21% Evoke PharmaOutperform Votes36058.16% Underperform Votes25941.84% Do analysts prefer BCAB or EVOK? BioAtla presently has a consensus price target of $6.00, suggesting a potential upside of 1,746.15%. Given BioAtla's stronger consensus rating and higher possible upside, research analysts plainly believe BioAtla is more favorable than Evoke Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Evoke Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in BCAB or EVOK? 77.2% of BioAtla shares are held by institutional investors. 11.5% of BioAtla shares are held by company insiders. Comparatively, 6.1% of Evoke Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryBioAtla beats Evoke Pharma on 13 of the 18 factors compared between the two stocks. Get Evoke Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVOK vs. The Competition Export to ExcelMetricEvoke PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.02M$6.27B$5.29B$7.35BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.186.6921.6917.68Price / Sales0.29222.71373.7492.91Price / CashN/A65.6738.1534.64Price / Book-0.225.776.363.94Net Income-$7.79M$142.01M$3.20B$247.45M7 Day Performance-10.22%5.79%3.92%3.17%1 Month Performance-42.12%-15.47%-10.36%-8.53%1 Year Performance-69.34%-10.99%10.42%0.31% Evoke Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOKEvoke Pharma0.3108 of 5 stars$2.15flatN/A-61.6%$3.21M$10.25M-0.204Short Interest ↑BCABBioAtla2.6711 of 5 stars$0.29+3.5%$6.00+1,968.3%-88.0%$14.03M$11M-0.1760Positive NewsMIRAMIRA Pharmaceuticals2.7397 of 5 stars$0.80-3.8%$14.00+1,643.9%+35.4%$13.50MN/A-1.432Short Interest ↓News CoverageGap DownME23andMe0.4011 of 5 stars$0.50-35.3%$9.40+1,787.6%-93.6%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeNRSNNeuroSense Therapeutics0.4609 of 5 stars$0.97-2.0%N/A-37.5%$13.26MN/A-1.5210Short Interest ↑CLDICalidi Biotherapeutics1.7341 of 5 stars$0.50flat$15.00+2,923.6%N/A$13.13M$50,000.000.0038Gap UpSLGLSol-Gel Technologies2.8512 of 5 stars$0.47+0.9%$5.00+963.8%-49.2%$13.09M$11.71M-1.3850News CoveragePositive NewsGap UpMEIPMEI Pharma2.266 of 5 stars$1.93-3.5%$7.00+262.7%-38.8%$12.86M$65.30M-0.34100Analyst ForecastShort Interest ↓News CoverageGap DownCOCPCocrystal Pharma2.5125 of 5 stars$1.26-11.3%$7.00+455.6%-10.3%$12.82MN/A-0.6810News CoveragePositive NewsGap DownSYBXSynlogic1.8908 of 5 stars$1.08flatN/A-43.9%$12.63M$8,000.00-0.2680Gap DownIPAImmunoPrecise Antibodies2.7091 of 5 stars$0.40+12.3%$4.00+889.6%-66.9%$12.56M$24.00M-0.5280Short Interest ↓Gap Down Related Companies and Tools Related Companies BCAB Alternatives MIRA Alternatives ME Alternatives NRSN Alternatives CLDI Alternatives SLGL Alternatives MEIP Alternatives COCP Alternatives SYBX Alternatives IPA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVOK) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
